tiprankstipranks
Advertisement
Advertisement

RPRX Stock Latest News

Royalty Pharma price target raised to $57 from $51 at UBS
The FlyRoyalty Pharma price target raised to $57 from $51 at UBS
7d ago
RPRX
Royalty Pharma: Leveraged Biopharma Catalysts and De-Risked Royalty Growth Support Further Upside
PremiumRatings
Royalty Pharma: Leveraged Biopharma Catalysts and De-Risked Royalty Growth Support Further Upside
7d ago
RPRX
Royalty Pharma Expands Daraxonrasib Royalty Stake After Milestone
PremiumCompany Announcements
Royalty Pharma Expands Daraxonrasib Royalty Stake After Milestone
15d ago
8K
RPRX
Royalty Pharma price target raised to $63 from $61 at Morgan Stanley
PremiumThe Fly
Royalty Pharma price target raised to $63 from $61 at Morgan Stanley
18d ago
RPRX
Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
PremiumThe Fly
Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
29d ago
JNJ
RPRX
Zymeworks price target raised to $48 from $33 at Evercore ISI
PremiumThe FlyZymeworks price target raised to $48 from $33 at Evercore ISI
2M ago
RPRX
ZYME
Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
Premium
The Fly
Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
2M ago
RPRX
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
Premium
The Fly
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
2M ago
ONC
JAZZ
Royalty Pharma price target raised to $50 from $45 at TD Cowen
PremiumThe Fly
Royalty Pharma price target raised to $50 from $45 at TD Cowen
2M ago
RPRX
The Week That Was, The Week Ahead: Macro and Markets, Feb. 15
PremiumMarket News
The Week That Was, The Week Ahead: Macro and Markets, Feb. 15
2M ago
J
W
Royalty Pharma Earnings Call Balances Strength And Risk
PremiumCompany Announcements
Royalty Pharma Earnings Call Balances Strength And Risk
2M ago
RPRX
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs
PremiumThe Fly
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs
2M ago
RPRX
Royalty Pharma price target raised to $61 from $56 at Morgan Stanley
PremiumThe FlyRoyalty Pharma price target raised to $61 from $56 at Morgan Stanley
2M ago
RPRX
Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B
Premium
The Fly
Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B
3M ago
RPRX
Royalty Pharma reports Q4 portfolio receipts of $874M
Premium
The Fly
Royalty Pharma reports Q4 portfolio receipts of $874M
3M ago
RPRX
Royalty Pharma PLC (RPRX) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Royalty Pharma PLC (RPRX) Q4 Earnings Cheat Sheet
3M ago
RPRX
Royalty Pharma upgraded to Buy from Neutral at UBS
PremiumThe Fly
Royalty Pharma upgraded to Buy from Neutral at UBS
3M ago
RPRX
Royalty Pharma price target raised to $50 from $48 at Citi
PremiumThe Fly
Royalty Pharma price target raised to $50 from $48 at Citi
3M ago
RPRX
Royalty Pharma provides update on business performance
PremiumThe Fly
Royalty Pharma provides update on business performance
4M ago
RPRX
Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
PremiumThe FlyRoyalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
4M ago
RPRX
TEVA
Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
Premium
The Fly
Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
4M ago
RPRX
Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
Premium
The Fly
Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
4M ago
CHRO
RPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >